天天舔天天爽_视频日韩_成人网线_天天草草草_免费一级在线观看_色综合色综合色综合色综合

嘉和生物藥業(yè) Genor Biopharma  
嘉和生物藥業(yè)有限公司成立于2007年12月，是一家創(chuàng)新驅(qū)動(dòng)型生物制藥公司，主要致力于治療性單克隆抗體、Fc-融合蛋白藥物的研發(fā)與產(chǎn)業(yè)化。

目前公司總投資已超過(guò)2億人民幣，員工約110人。嘉和產(chǎn)品線(xiàn)現(xiàn)有10余個(gè)在研產(chǎn)品，其中3個(gè)在研產(chǎn)品處于臨床試驗(yàn)或者臨床報(bào)批階段。嘉和擁有6000 多平米的研發(fā)中心、工藝開(kāi)發(fā)中心、質(zhì)量分析中心和cGMP臨床藥品生產(chǎn)基地，并正在規(guī)劃建設(shè)規(guī)模化的cGMP商業(yè)生產(chǎn)基地。

嘉和擁有一支經(jīng)驗(yàn)豐富并且搭配完整的資深專(zhuān)家組成的核心團(tuán)隊(duì)，其成員專(zhuān)業(yè)經(jīng)驗(yàn)涵蓋了單抗藥物研發(fā)的各個(gè)關(guān)鍵環(huán)節(jié)。他們都來(lái)自Amgen, Abbott等國(guó)外著名生物制藥公司，均具有15~20年左右的工業(yè)界經(jīng)驗(yàn)。

合作是嘉和公司發(fā)展策略的關(guān)鍵組成部分。除了內(nèi)部研發(fā)以外，我們還積極尋求項(xiàng)目引進(jìn)、合作開(kāi)發(fā)以及建立合資企業(yè)等機(jī)會(huì)，以豐富公司的產(chǎn)品線(xiàn)；同時(shí)，我們也積極尋求產(chǎn)品輸出及其他創(chuàng)新性合作模式的機(jī)會(huì)，以推進(jìn)嘉和產(chǎn)品進(jìn)入其他新興市場(chǎng)和/或歐美市場(chǎng)。


Founded in December 2007, Genor Biopharma is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs.

With a total investment of about 30 million USD, Genor Biopharma now has ~ 10 products in pipeline (Three at clinical trial/IND stage), about 110 employees, and more than 6000 m2 of space including R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility. A commercial scale cGMP production facility is also under active planning.

Genor Biopharma has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15~20 years of hand-on working experience at leading western biopharmas such as Amgen, Abbott etc.

Partnership is an intrinsic part of Genor Biopharma’s coporate strategy. Besides in-house R&D we actively seek in-licensing, co-development or JV opportunities to strengthen our pipeline. In the same time, we are also actively exploring out-licensing and other creative collaboration models to help propel Genor products into other emerging markets and/or western markets.